文献速递乳腺癌

早期复发三阴性乳腺癌患者的真实世界临床与生存结局:来自ESME全国队列研究

Real-world clinical and survival outcomes of patients with early relapsed triple-negative breast cancer from the ESME national cohort.
PubMed 文献 · Eur J Cancer · 2023-06-07

基于法国ESME多中心观察性队列(NCT03275311),纳入2008至2020年新辅助/辅助蒽环类和/或紫杉类化疗后复发转移的三阴性乳腺癌患者。早期复发(化疗结束后12个月内)占46%(881例),中位OS为10.1个月 vs 晚期复发17.1个月(aHR 1.92),中位PFS1为3.1个月 vs 5.3个月(aHR 1.66)。

要点

  • 早期复发(≤12个月)占转移性三阴性乳腺癌的46%,且随时间保持稳定。
  • 早期复发患者中位OS 10.1个月,显著低于晚期复发的17.1个月(aHR 1.92)。
  • 早期复发患者中位PFS1 3.1个月,显著低于晚期复发的5.3个月(aHR 1.66)。

核心结论

  • 这些真实世界数据提供了强有力证据,表明早期复发的转移性三阴性乳腺癌预后极差、治疗耐药性更高且存在重大未满足的医疗需求。

研究设计与样本

  • ESME-MBC数据库是一项多中心、全国性、观察性队列研究(NCT03275311)。
  • 纳入2008至2020年诊断为转移性三阴性乳腺癌、且为新辅助/辅助蒽环类和/或紫杉类化疗后复发的所有ESME患者。
  • 早期复发定义为新辅助/辅助蒽环类和/或紫杉类化疗结束后12个月内诊断转移。
  • 早期复发组881例(46%),晚期复发(≥12个月)组1045例。

主要发现

  • 早期复发患者较晚期复发患者更年轻,且初诊时肿瘤负荷更大。
  • 早期复发率随时间保持稳定。
  • 早期复发组中位OS为10.1个月(95%CI 9.3-10.9),晚期复发组为17.1个月(95%CI 15.7-18.2);aHR 1.92(95%CI 1.73-2.13),p<0.001。
  • 早期复发组中位PFS1为3.1个月(95%CI 2.9-3.4),晚期复发组为5.3个月(95%CI 5.1-5.8);aHR 1.66(95%CI 1.50-1.83),p<0.001。
  • 在早期复发患者中,转移部位数目更多和内脏转移与更差的OS独立相关,而治疗类型与OS无独立关联。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Early metastatic relapse of triple-negative breast cancer (mTNBC) after anthracyclins and/or taxanes based (A/T) primary treatment represents a highly aggressive cancer situation requiring urgent characterisation and handling. Epidemio-Strategy-Medico-Economical-Metastatic Breast Cancer (ESME-MBC) database, a multicenter, national, observational cohort (NCT03275311) provides recent data on this entity. METHODS: All ESME patients diagnosed between 2008 and 2020 with mTNBC occurring as a relapse after a systemic neoadjuvant/adjuvant taxane and/or anthracycline-based chemotherapy were included. Early relapses were defined by a metastatic diagnosis up to 12 months of the end of neo/adjuvant A/T chemotherapy. We assessed overall survival (OS) and progression-free-survival under first-line treatment (PFS1) by early versus late relapse (≥12 months). RESULTS: Patients with early relapse (N = 881, 46%) were younger and had a larger tumour burden at primary diagnosis than those with late relapses (N = 1045). Early relapse rates appeared stable over time. Median OS was 10.1 months (95% CI 9.3-10.9) in patients with early relapse versus 17.1 months (95% CI 15.7-18.2) in those with late relapse (adjusted hazard-ratio (aHR): 1.92 (95% CI 1.73-2.13); p < 0.001). The median PFS1 was respectively 3.1 months (95% CI 2.9-3.4) and 5.3 months (95% CI 5.1-5.8); (aHR: 1.66; [95% CI 1.50-1.83]; p < 0.001). Among early relapsed patients, a higher number of metastatic sites, visceral disease but not treatment types, were independently associated with a poorer OS. CONCLUSION: These real-world data provide strong evidence on the dismal prognosis, higher treatment resistance and major unmet medical need associated with early relapsed mTNBC. Database registration: clinicaltrials.gov Identifier NCT032753.

来源:Eur J Cancer,查看原文。版权归原作者所有。

引用

  1. Grinda T, Antoine A, Jacot W, et al. Real-world clinical and survival outcomes of patients with early relapsed triple-negative breast cancer from the ESME national cohort. Eur J Cancer. 2023. PMID: 37385070. doi:10.1016/j.ejca.2023.05.023

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。